Search results for "Glycemic"

showing 10 items of 331 documents

A high dietary glycemic index increases total mortality in a Mediterranean population at high cardiovascular risk

2014

© 2014 Castro-Quezada et al. Objective: Different types of carbohydrates have diverse glycemic response, thus glycemic index (GI) and glycemic load (GL) are used to assess this variation. The impact of dietary GI and GL in all-cause mortality is unknown. The objective of this study was to estimate the association between dietary GI and GL and risk of all-cause mortality in the PREDIMED study. Material and Methods: The PREDIMED study is a randomized nutritional intervention trial for primary cardiovascular prevention based on community-dwelling men and women at high risk of cardiovascular disease. Dietary information was collected at baseline and yearly using a validated 137-item food freque…

GerontologyMalePhysiologyEpidemiologymodelos de riesgos proporcionaleshumanoslcsh:MedicineDieta mediterràniaFatsElderlyRisk Factorsíndice glucémicoCause of DeathMedicine and Health SciencesMedicinelcsh:Sciencemediana edadAged 80 and overeducation.field_of_studyancianoMultidisciplinaryDeath ratesGeographyGeographical regionsdietaMortality rateHazard ratioRegional geographyAge FactorsMiddle AgedGlycemic indexCardiovascular diseasesQuartilePhysiological ParametersCardiovascular DiseasesFemaleDietaResearch Articlemedicine.medical_specialtyPopulationCarbohydratesenfermedades cardiovascularesBlood sugarNational Death Indexcausas de muerteInternal medicineGlycemic loadDietary CarbohydratesMortalitatHumansfactores de riesgoObesityFatty acidsMortalityeducationCardiovascular Disease EpidemiologyGlycemicNutritionAgedProportional Hazards Modelsconducta alimentariabusiness.industryPhysical activitycarbohidratos dietéticosMalalties cardiovascularslcsh:RBody WeightBiology and Life SciencesPREDIMED studyNutrientsFeeding BehaviorGenitourinary cancersDietEarth sciencesGlucèmiaGeriatricsGlycemic IndexGlycemiclcsh:QMediterranean Basinbusinesshuman activities
researchProduct

Glycated Albumin for Glycemic Control in T2DM Population: A Multi-Dimensional Evaluation.

2021

Lucrezia Ferrario,1 Fabrizio Schettini,1 Angelo Avogaro,2 Chiara Bellia,3 Federico Bertuzzi,4 Graziella Bonetti,5 Antonio Ceriello,6 Marcello Ciaccio,3,7 Massimiliano Corsi Romanelli,8,9 Elena Dozio,9 Luca Falqui,10 Angela Girelli,11 Antonio Nicolucci,12 Gianluca Perseghin,13,14 Mario Plebani,15 Umberto Valentini,11 Martina Zaninotto,15 Silvana Castaldi,9,16 Emanuela Foglia1 1Centre for Health Economics, Social and Health Care Management, Università Carlo Cattaneo - LIUC, Castellanza, Italy; 2Department of Medicine, University-Hospital of Padova, Padova, Italy; 3Section of Clinical Biochemistry and Clinical Molecular Medicine, Department of Biopathology and Medical Biotechnologie…

GerontologyMedicine (General)economic evaluationtype 2 diabetes mellitusEconomics Econometrics and Finance (miscellaneous)PopulationT2DMRM1-950multidimensional approach03 medical and health sciencesR5-9200302 clinical medicineClinical pathwayQuality of lifeMedicine030212 general & internal medicineeducationMED/13 - ENDOCRINOLOGIAGlycemicOriginal Researcheducation.field_of_studyHealth economicsbusiness.industry030503 health policy & servicesHealth PolicyHealth technologyType 2 Diabetes MellitusHealth Technology AssessmentClinicoEconomics and Outcomes ResearchType 2 diabetes mellituEconomic evaluationglycated albuminTherapeutics. Pharmacology0305 other medical sciencebusinessClinicoEconomics and outcomes research : CEOR
researchProduct

LC-ESI/HRMS analysis of glucosinolates, oxylipins and phenols in Italian rocket salad (Diplotaxis erucoides subsp. erucoides (L.) DC.) and evaluation…

2021

BACKGROUND: This study investigated the chemical profile and biological activity of Diplotaxis erucoides subsp. erucoides (L.) DC. (Brassicaceae) collected in Sicily (Italy). RESULTS: Liquid chromatography coupled with electrospray ionization and high-resolution mass spectrometry (LC-ESI/HRMS) analysis of the ethanol extract revealed the presence of 42 compounds – glucosinolates, hydroxycinnamic acids, flavonoids, and oxylipins. The extract was tested for its antioxidant activity using 2,2-diphenyl-1-picrylhydrazyl (DPPH), 2,2′-azinobis(3-ethylbenzothiazoline-6-sulfonic) acid (ABTS), ferric reducing ability power (FRAP), and β-carotene bleaching tests. Promising protection from lipid peroxi…

Glucosinolatesantioxidant activityantioxidant activity; Diplotaxis erucoides; hypoglycemic and hypolipidemic effect; LC-ESI/HRMS analysis; Antioxidants; Brassicaceae; Chromatography Liquid; Enzyme Inhibitors; Flavonoids; Glucosinolates; Glycoside Hydrolase Inhibitors; Humans; Mass Spectrometry; Oxylipins; Plant Extracts; Salads; Sicily; alpha-Amylases; alpha-GlucosidasesAntioxidantsMass SpectrometrySettore BIO/01 - Botanica GeneraleLC-ESI/HRMS analysisHumansGlycoside Hydrolase InhibitorsOxylipinsEnzyme InhibitorsSicilyFlavonoidsChromatographyLiquidPlant ExtractsSettore BIO/02 - Botanica Sistematicaalpha-GlucosidasesSettore CHIM/06 - Chimica Organicahypoglycemic and hypolipidemic effectBrassicaceaeSettore BIO/03 - Botanica Ambientale E ApplicataDiplotaxis erucoidesSaladsalpha-AmylasesChromatography Liquid
researchProduct

Behavioral medicine interventions in diabetes.

2010

Poor glycemic control is prevalent in the majority of patients with diabetes and has a strong impact on medical as well as psychological outcomes. Psychological and behavioral variables are of particular interest, as the patients themselves are the most determining factor of treatment success. Consequently, a wide range of behavioral medicine interventions are aimed at improvement in diabetes self-management, coping strategies, blood glucose awareness, and stress reduction. This review provides an overview of randomized controlled trials (RCTs) published in the past 18 months (from March 2008 to September 2009) that evaluated behavioral medicine interventions in patients with diabetes. The …

Glycated Hemoglobinbusiness.industryHealth BehaviorPsychological interventionMEDLINEHealth Promotionmedicine.diseaseSelf CarePsychiatry and Mental healthHealth promotionPatient Education as TopicDiabetes mellitusBehavioral medicineSelf careDiabetes MellitusMedicineHumansPatient ComplianceHealth behaviorbusinessGlycemicClinical psychologyCurrent opinion in psychiatry
researchProduct

Pancreatic Extracts for the Treatment of Diabetes (1889-1914): Acomatol.

2019

Background Historical review on the early development of organotherapy for diabetes [pancreatic extracts (PE)] and its relationship with the social and political circumstances. Areas of uncertainty The diagnosis of diabetes relied only in the presence of glycosuria and cardinal symptoms. Blood glucose determinations were not regularly available, requiring large volumes for sampling. Micromethods for glycemia were developed just in the last years of the investigated period. Hypoglycemia remains undiscovered. Isolation and purification of PE were difficult tasks due to the unknown chemical structure of the antidiabetic hormone. Data sources (1) Berliner Medizinhistoriches Museum der Charite (…

GlycosuriaBlood Glucosemedicine.medical_specialtyPancreatic diseasemedicine.medical_treatmentMEDLINEPancreatic Extracts030204 cardiovascular system & hematologyHypoglycemia03 medical and health sciences0302 clinical medicineEndocrinologyDiabetes mellitusmedicineDiabetes MellitusHumansHypoglycemic AgentsPharmacology (medical)030212 general & internal medicinePancreasPharmacologybusiness.industryHistory 19th CenturyGeneral MedicineHistory 20th CenturyOrganotherapymedicine.diseaseEndocrine pharmacologyFamily medicinePancreatectomymedicine.symptombusinessAmerican journal of therapeutics
researchProduct

Synthesis and evaluation of a glibenclamide glucose-conjugate: a potential new lead compound for substituted glibenclamide derivatives as islet imagi…

2007

The search for novel SUR1-ligands originates from the idea to influence the in vivo behaviour by adding new structural moieties to the glibenclamide structure while preserving its binding affinity. Important application of novel conjugates might be their use as radioactively labelled tracer probes in the non-invasive investigation of the islet mass. It is known that the imaging quality of a tracer could be improved by increasing its hydrophilicity, which leads to a reduced plasma protein binding and diminished the unspecific uptake by various organs. In this study the glucose molecule was chosen as a substitute of glibenclamide to enhance hydrophilicity. As expected glucose conjugation lead…

GlycosylationPotassium ChannelsTime FactorsPhysiologyReceptors DrugClinical BiochemistryPlasma protein bindingSulfonylurea ReceptorsBiochemistryBinding CompetitiveGlibenclamideCellular and Molecular Neurosciencechemistry.chemical_compoundIslets of LangerhansEndocrinologyIn vivoChlorocebus aethiopsGlyburidemedicineAnimalsHumansHypoglycemic AgentsInsulinPotassium Channels Inwardly Rectifyinggeographygeography.geographical_feature_categoryMolecular StructureLigand (biochemistry)IsletRatsGlucosechemistryBiochemistryCOS CellsATP-Binding Cassette TransportersLead compoundConjugatemedicine.drugRegulatory peptides
researchProduct

12-month follow-up analysis of a multicenter, randomized, prospective trial in de novo liver transplant recipients (LIS2T) comparing cyclosporine mic…

2006

The LIS2T study was an open-label, multicenter study in which recipients of a primary liver transplant were randomized to cyclosporine microemulsion (CsA-ME) (Neoral) (n = 250) (monitoring of blood concentration at 2 hours postdose) C2 or tacrolimus (n = 245) (monitoring of trough drug blood level [predose]) C0 to compare efficacy and safety at 3 and 6 months and to evaluate patient status at 12 months. All patients received steroids with or without azathioprine. At 12 months, 85% of CsA-ME patients and 86% of tacrolimus patients survived with a functioning graft (P not significant). Efficacy was similar in deceased- and living-donor recipients. Significantly fewer hepatitis C–positive pati…

Graft RejectionMaleTime Factorsmedicine.medical_treatmentTACROLIMUSAzathioprineHepacivirusHEPATITIS-CLiver transplantationmedicine.disease_causeGastroenterologychemistry.chemical_compoundLiving DonorsLongitudinal StudiesC-2IMMUNOSUPPRESSIONHEPATITIS-C DIABETES-MELLITUS C-2 REPLICATION RECURRENCE SURVIVALGraft SurvivalHepatitis CTreatment Outcomesurgical procedures operativeCreatinineSURVIVALEmulsionsFemaleSteroidsImmunosuppressive Agentsmedicine.drugmedicine.medical_specialtyHepatitis C virusRenal functionRANDOMIZED STUDYAge DistributionInternal medicinemedicineDiabetes MellitusHumansHypoglycemic AgentsRECURRENCEMonitoring PhysiologicHepatitisTransplantationCreatinineHepatologybusiness.industryLIVER TRANSPLANTATIONDIABETES-MELLITUSmedicine.diseaseSurvival AnalysisTacrolimusSurgerychemistryREPLICATIONCYCLOSPORINESurgerybusinessFollow-Up Studies
researchProduct

Impact pronostique de l’HbA1c et de la glycémie plasmatique (Gp) à la phase aiguë d’un infarctus du myocarde sur la mortalité à un an chez des patien…

2020

International audience; Background: The usefulness of the combined assessment of HbA1c and plasma glucose (PG) in acute myocardial infarction (AMI) in non-diabetic patients remains unclear.Purpose: In a large observational study, we aimed to identify the prognostic values of these biomarkers regarding one-year all-cause mortality in non-diabetic patients after AMI.Methods: From the "obseRvatoire des Infarctus de Côte d'Or" (RICO) survey database, we included all consecutive non-diabetic patients with AMI (n=6617) from May 2001 to December 2016. Exclusion criteria were: admission known or unknown diabetes, in-hospital death. The primary endpoint was all-cause one-year mortality. The secondar…

Gynecologymedicine.medical_specialtyHbA1cbusiness.industryGlycemic stress[SDV]Life Sciences [q-bio]Non-diabetic030204 cardiovascular system & hematologyMyocardial infraction3. Good health[SDV] Life Sciences [q-bio]One year mortality03 medical and health sciencesOne-year mortality0302 clinical medicineMedicineCardiology and Cardiovascular MedicinebusinessNon diabetic
researchProduct

Efficacy and Safety of Degludec versus Glargine in Type 2 Diabetes.

2017

BACKGROUND Degludec is an ultralong-Acting, once-daily basal insulin that is approved for use in adults, adolescents, and children with diabetes. Previous open-label studies have shown lower day-To-day variability in the glucose-lowering effect and lower rates of hypoglycemia among patients who received degludec than among those who received basal insulin glargine. However, data are lacking on the cardiovascular safety of degludec. METHODS We randomly assigned 7637 patients with type 2 diabetes to receive either insulin degludec (3818 patients) or insulin glargine U100 (3819 patients) once daily between dinner and bedtime in a double-blind, treat-To-Target, event-driven cardiovascular outco…

Insulin degludecBlood GlucoseMalemedicine.medical_treatmentDEVOTE Study GroupInsulin GlargineType 2 diabetesKaplan-Meier Estimate030204 cardiovascular system & hematologylaw.inventiondiabetes ; insulin0302 clinical medicineRandomized controlled triallawCardiovascular DiseaseGLUCOSE CONTROL11 Medical and Health SciencesRISKCOMPLICATIONSOUTCOMESIncidenceGeneral MedicineMiddle AgedInsulin Long-ActingVARIABILITYCardiovascular Diseasesdiabetes mellitusFemaleLife Sciences & BiomedicineHumanmedicine.drugmedicine.medical_specialty030209 endocrinology & metabolismAged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus Type 2; Double-Blind Method; Female; Humans; Hypoglycemia; Hypoglycemic Agents; Incidence; Insulin Glargine; Insulin Long-Acting; Kaplan-Meier Estimate; Male; Middle Aged; Medicine (all)HypoglycemiaBedtimeArticleEVENTS03 medical and health sciencesHYPOGLYCEMIAMedicine General & InternalDouble-Blind MethodInternal medicineDiabetes mellitusGeneral & Internal MedicinemedicineHumansHypoglycemic AgentsIntensive care medicineMETAANALYSISAgedScience & TechnologyHypoglycemic AgentInsulin glarginebusiness.industryInsulinmedicine.diseaseDiabetes Mellitus Type 2businessBASAL INSULIN
researchProduct

Insulin degludec and insulin glargine 300 U/mL: Which of these two insulins causes less hypoglycemia?

2019

The interesting article by Yamabe et al.1 showed, using continuous glucose monitoring, that insulin degludec (I‐Deg) was associated with a high percentage of time with nocturnal hypoglycemia than with insulin glargine 300 U/mL (I‐G300; P = 0.02). However, we observe that some possible confounding factors might have influenced the results, such as differences in concomitant medications, use of the same titration protocol for both kinds of insulin or differences in glucose levels. This is also a recurrent problem in clinical trials, which sometime produce conflicting results. In fact, the study of Yamabe et al. is partly in agreement with some recently published clinical trials that gave diff…

Insulin degludecBlood Glucosemedicine.medical_specialtyendocrine system diseasesEndocrinology Diabetes and Metabolismmedicine.medical_treatmentdiabetes insulin clinical trials hypoglicemiaInsulinsInsulin GlargineHypoglycemiaDiseases of the endocrine glands. Clinical endocrinologyInternal medicineDiabetes mellitusInternal MedicinemedicineHumansHypoglycemic AgentsLetters to the EditorLetter to the EditorGlycated HemoglobinInsulin glarginebusiness.industryInsulinBlood Glucose Self-Monitoringnutritional and metabolic diseasesGeneral Medicinemedicine.diseaseRC648-665HypoglycemiaClinical trialInsulin Long-ActingEndocrinologyDiabetes Mellitus Type 2businessmedicine.drug
researchProduct